Evolution of the Average Target: Ironwood Pharmaceuticals, Inc.

Evolution of the Average Target - Ironwood Pharmaceuticals, Inc.

Evolution of the Target Price: Ironwood Pharmaceuticals, Inc.

Evolution of the Target Price - Ironwood Pharmaceuticals, Inc.

Changes in Analyst Recommendations: Ironwood Pharmaceuticals, Inc.

af523d5686279b53615bacbdd84da0.HX8-J9DRM8HHT2Rzawji8O9EBorxr5fm4CpTxgmCDAc.XhBzY7qLAY6iDBBEEVDQlKAKX-mU36eMq0sjhWCybkZZOnF9gIAEkoMVXA~be37049fa420637926cfa5f5b1f2ca19
06/11 AbbVie, Ironwood Win FDA Approval for Linzess to Treat Children With Irritable Bowel Syndrome With Constipation MT
07/08/25 Ironwood Pharmaceuticals Q2 revenue beats expectations RE
15/04/25 Wells Fargo Downgrades Ironwood Pharmaceuticals to Equalweight From Overweight, Adjusts Price Target to $1 From $7 MT
15/04/25 Jefferies Downgrades Ironwood Pharmaceuticals to Hold From Buy, Adjusts Price Target to $0.70 From $8 MT
09/09/24 Leerink Partners Initiates Coverage on Ironwood Pharmaceuticals With Market Perform Rating, $5 Price Target MT
17/02/24 Piper Sandler Adjusts Price Target on Ironwood Pharmaceuticals to $21 From $20, Maintains Overweight Rating MT
18/01/24 Craig-Hallum Starts Coverage on Ironwood Pharmaceuticals with Buy Rating, $21 Price Target MT
28/09/23 JMP Securities Starts Ironwood Pharmaceuticals at Market Outperform, $22 Price Target MT
23/05/23 Piper Sandler Adjusts Price Target on Ironwood Pharmaceuticals to $19 From $16, Maintains Overweight Rating MT
02/09/22 Capital One Securities Initiates IRWD at Overweight with $15 Price Target MT
17/08/22 Wells Fargo Adjusts Ironwood Pharmaceuticals' Price Target to $13 from $12, Maintains Equalweight Rating MT
22/04/22 Piper Sandler Starts Ironwood Pharmaceuticals at Overweight With $16 Price Target MT
13/10/21 Ironwood Pharmaceuticals : Morgan Stanley Adjusts Price Target on Ironwood Pharmaceuticals to $14 From $13, Maintains Equal-Weight Rating MT
17/07/21 Ironwood Pharmaceuticals : Morgan Stanley Adjusts Price Target on Ironwood Pharmaceuticals to $12 From $11, Maintains Equal-Weight Rating MT
07/11/20 Ironwood Pharmaceuticals : Morgan Stanley Adjusts Ironwood Pharmaceuticals' Price Target to $12 from $11, Keeps Equalweight Rating MT
07/11/20 Ironwood Pharmaceuticals : Credit Suisse Adjusts Ironwood Pharmaceuticals' Price Target to $12 From $11, Maintains Neutral Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+27.32%
+2.58%
-1.11%
+6.64%
-3.15%
+11.81%
-4.82%
+16.44%
-6.38%
+4.98%
Average +5.43%
Weighted average by Cap. +2.73%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
4.850USD
Average target price
6.175USD
Spread / Average Target
+27.32%
High Price Target
10.00USD
Spread / Highest target
+106.19%
Low Price Target
3.700USD
Spread / Lowest Target
-23.71%

Analyst Consensus Detail

Analyst consensus - Ironwood Pharmaceuticals, Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Ironwood Pharmaceuticals, Inc.
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Ironwood Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. IRWD Stock
  4. Consensus Ironwood Pharmaceuticals, Inc.